Overcoming cancer therapeutic bottleneck by drug repurposing

Z Zhang, L Zhou, N Xie, EC Nice, T Zhang… - Signal transduction and …, 2020 - nature.com
Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

The PTEN conundrum: how to target PTEN-deficient prostate cancer

DJ Turnham, N Bullock, MS Dass, JN Staffurth… - Cells, 2020 - mdpi.com
Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome
10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to …

Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and src family kinase YES in rhabdomyosarcoma

S Akshintala, RT Sundby, D Bernstein, JW Glod… - Clinical cancer …, 2023 - AACR
Purpose: Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown
meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The …

Emerging role of IGF-1 in prostate cancer: a promising biomarker and therapeutic target

G Liu, M Zhu, M Zhang, F Pan - Cancers, 2023 - mdpi.com
Simple Summary Prostate cancer (PCa) affects millions of men globally, and approximately
20% of PCa patients are found after they develop into a lethal metastatic or castration …

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

VM Macaulay, S Lord, S Hussain, JP Maroto… - British Journal of …, 2023 - nature.com
Background This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth
factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate …

[HTML][HTML] Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: a review article

J Cham, AR Venkateswaran, M Bhangoo - Clinical Genitourinary Cancer, 2021 - Elsevier
Background Prostate cancer is one of leading causes of cancer death among men
worldwide. Androgen deprivation therapy is a central part of the prostate cancer treatment …

[HTML][HTML] Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer

M Wylaź, A Kaczmarska, D Pajor, M Hryniewicki… - Biomedicine & …, 2023 - Elsevier
Breast cancer (BC) and prostate cancer (PC) are at the top of the list when it comes to the
most common types of cancers worldwide. The phosphatidylinositol 3-kinase (PI3K)/protein …

Inflammation in urological malignancies: the silent killer

M Catalano, G Roviello, R Santi, D Villari… - International Journal of …, 2023 - mdpi.com
Several studies have investigated the role of inflammation in promoting tumorigenesis and
cancer progression. Neoplastic as well as surrounding stromal and inflammatory cells …

Recent advances and future directions in anti‐tumor activity of cryptotanshinone: A mechanistic review

M Ashrafizadeh, A Zarrabi, S Orouei… - Phytotherapy …, 2021 - Wiley Online Library
In respect to the enhanced incidence rate of cancer worldwide, studies have focused on
cancer therapy using novel strategies. Chemotherapy is a common strategy in cancer …

The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy

G Lemos, CMAS Fernandes, FH Silva… - Prostate Cancer and …, 2024 - nature.com
Background Autophagy is a well-conserved catabolic process that plays a key role in cell
homeostasis. In the prostate, defective autophagy has been implicated in the genesis and …